Combination of cyclin-dependent kinase 4/6 inhibitors and renin-angiotensin system inhibitors in breast cancer treatment: a promising therapeutic approach
Emel Mutlu, Mevlüde İnanç · 2025
Read Combination of cyclin-dependent kinase 4/6 inhibitors and renin-angiotensin system inhibitors in breast cancer treatment: a promising therapeutic approach by Emel Mutlu, Mevlüde İnanç (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12711125.txt.
Description
Emel Mutlu and Mevlüde İnanç test whether common blood pressure drugs quietly boost a modern breast cancer therapy. CDK4/6 inhibitors have improved outlooks in metastatic breast cancer. Renin-angiotensin system blockers, taken widely for hypertension and heart failure, may also starve tumors by trimming their blood vessel growth. Their 2025 study reviews records of metastatic patients on CDK4/6 therapy.
Patients are split by whether they also took one of the blood pressure drug classes. Outcomes are compared across the groups, looking for a synergy the lab rationale predicts. The approach is cheap pharmacology: both drug families are generic, familiar, and already sitting in many patients' cabinets. Oncologists get early clinical evidence for a pairing born from a side observation.
Catalog record
| CREATOR | Emel Mutlu, Mevlüde İnanç |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |